IDiyas

For the Inventor, By the Inventor

FR

Cellectis S.a.


USPTO Granted Patents = 18


Trademarks = 1

Forward Citations = 52

Loading Chart...
Loading Chart...

46 inventors (with patents filed for the assignee):

goldMedal Philippe Duchateau (6 out of 52 patents)

silverMedal Jean-Charles Epinat (5 out of 12 patents)

bronzeMedal Alan D King (4 out of 11 patents)

4.  Sylvain Arnould (4 out of 5 patents)

5.  Patrick Chames (4 out of 5 patents)

6.  Emmanuel Lacroix (4 out of 6 patents)

7.  Richard E Walters (3 out of 16 patents)

8.  Phillippe Duchateau (3 out of 3 patents)

9.  Frederic Paques (3 out of 6 patents)

10.  Marc-Andre D'Aoust (2 out of 34 patents)

11.  Daniel F Voytas (2 out of 28 patents)

12.  Claudia Bertonati (2 out of 7 patents)

13.  Alexandre Juillerat (2 out of 19 patents)

14.  Thomas Stoddard (2 out of 4 patents)

15.  Luc Mathis (2 out of 6 patents)


18 patents:

1. 12133867 - Universal anti-CD22 chimeric antigen receptor engineered immune cells (2024-11-05),
2. 11944643 - Universal anti-CD22 chimeric antigen receptor engineered immune cells (2024-04-02),
3. 11778993 - Repeat variable diresidues for targeting nucleotides (2023-10-10),
4. 11690873 - Universal chimeric antigen receptor T cells specific for CD22 (2023-07-04),
5. 11578318 - Large volume ex vivo electroporation method (2023-02-14),
6. 11576317 - Mutantplant or cell with reduced XylT and FucT (2023-02-14),
7. 11555198 - Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases (2023-01-17),
8. 10494626 - Dynamic mixing and electroporation chamber and system (2019-12-03),
9. 9982251 - Large volume ex vivo electroporation method (2018-05-29),
10. 9315788 - Method for the generation of compact TALE-nucleases and uses thereof (2016-04-19),
11. 9044492 - Method for modulating the efficiency of double-strand break-induced mutagenesis (2015-06-02),
12. 8927247 - [object Object] (2015-01-06),
13. 8697395 - Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof (2014-04-15),
14. 8624000 - Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof (2014-01-07),
15. 8530214 - Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof (2013-09-10),
Cellectis is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company utilizes its proprietary gene editing technologies to develop CAR-T and TALEN-based products that enable the body's immune system to target and eliminate cancer cells. With a diverse pipeline of candidate therapies and ongoing clinical trials, Cellectis aims to revolutionize cancer treatment and improve patient outcomes through precision medicine.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

18 Patents

#69 in

#1,069 in France

#33,129 in the World

...
FR

Cellectis S.a.

Forward Citations = 52

46 inventors:

goldMedal Philippe Duchateau (6 out of 52 patents)

silverMedal Jean-Charles Epinat (5 out of 12 patents)

bronzeMedal Alan D King (4 out of 11 patents)

4.  Sylvain Arnould (4 out of 5 patents)

5.  Patrick Chames (4 out of 5 patents)

Please report any incorrect information to support@idiyas.com
Loading…